Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes.

Nishimura Y, Mieda H, Ishii J, Ogino C, Fujiwara T, Kondo A.

J Nanobiotechnology. 2013 Jun 24;11:19. doi: 10.1186/1477-3155-11-19.

2.

Complex carriers of affibody-displaying bio-nanocapsules and composition-varied liposomes for HER2-expressing breast cancer cell-specific protein delivery.

Nishimura Y, Ishii J, Okazaki F, Ogino C, Kondo A.

J Drug Target. 2012 Dec;20(10):897-905. doi: 10.3109/1061186X.2012.725404. Epub 2012 Oct 1.

PMID:
23020553
3.

[Bio-nanocapsules for in vivo pinpoint drug delivery].

Jung J, Kasuya T, Tanizawa K, Kuroda S.

Yakugaku Zasshi. 2007 May;127(5):797-805. Review. Japanese.

4.

Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.

Shishido T, Mieda H, Hwang SY, Nishimura Y, Tanaka T, Ogino C, Fukuda H, Kondo A.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5726-31. doi: 10.1016/j.bmcl.2010.08.011. Epub 2010 Aug 6.

PMID:
20801029
5.

Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials.

Jung J, Matsuzaki T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S.

J Control Release. 2008 Mar 20;126(3):255-64. doi: 10.1016/j.jconrel.2007.12.002. Epub 2007 Dec 14.

PMID:
18207275
6.

Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.

Dou S, Yao YD, Yang XZ, Sun TM, Mao CQ, Song EW, Wang J.

J Control Release. 2012 Aug 10;161(3):875-83. doi: 10.1016/j.jconrel.2012.05.015. Epub 2012 May 14.

PMID:
22762887
7.

A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway.

Nishimura Y, Takeda K, Ezawa R, Ishii J, Ogino C, Kondo A.

J Nanobiotechnology. 2014 Apr 1;12:11. doi: 10.1186/1477-3155-12-11.

8.

Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.

Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y.

Eur J Pharm Biopharm. 2008 Nov;70(3):718-25. doi: 10.1016/j.ejpb.2008.06.026. Epub 2008 Jul 4.

PMID:
18647651
9.

Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules.

Herringson TP, Altin JG.

J Control Release. 2009 Nov 3;139(3):229-38. doi: 10.1016/j.jconrel.2009.06.034. Epub 2009 Jul 10.

PMID:
19595724
10.

Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes.

Bedi D, Musacchio T, Fagbohun OA, Gillespie JW, Deinnocentes P, Bird RC, Bookbinder L, Torchilin VP, Petrenko VA.

Nanomedicine. 2011 Jun;7(3):315-23. doi: 10.1016/j.nano.2010.10.004. Epub 2010 Nov 2.

11.

Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.

Lin Q, Jin CS, Huang H, Ding L, Zhang Z, Chen J, Zheng G.

Small. 2014 Aug 13;10(15):3072-82. doi: 10.1002/smll.201303842. Epub 2014 Apr 6.

PMID:
24706435
12.

Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells.

Hoelters J, Ciccarella M, Drechsel M, Geissler C, Gülkan H, Böcker W, Schieker M, Jochum M, Neth P.

J Gene Med. 2005 Jun;7(6):718-28.

PMID:
15712343
13.
14.

Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.

Spagnou S, Miller AD, Keller M.

Biochemistry. 2004 Oct 26;43(42):13348-56.

PMID:
15491141
15.

Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptide-dsRNA binding domain.

Li H, Zheng X, Koren V, Vashist YK, Tsui TY.

Int J Pharm. 2014 Jul 20;469(1):206-13. doi: 10.1016/j.ijpharm.2014.04.050. Epub 2014 Apr 23.

PMID:
24768403
16.

[Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3].

Ren SH, Zhang W, Qu P, Liu Y, Wang JW, Zhang L.

Ai Zheng. 2005 Oct;24(10):1173-8. Chinese.

PMID:
16219128
17.

TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.

Keates AC, Fruehauf J, Xiang S, Li CJ.

Biotechnol Genet Eng Rev. 2008;25:113-27. Review.

PMID:
21412352
18.

Chapter 8 - Bio-nanocapsule-liposome conjugates for in vivo pinpoint drug and gene delivery.

Kasuya T, Jung J, Kinoshita R, Goh Y, Matsuzaki T, Iijima M, Yoshimoto N, Tanizawa K, Kuroda S.

Methods Enzymol. 2009;464:147-66. doi: 10.1016/S0076-6879(09)64008-8.

PMID:
19903554
19.

The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex.

Tagami T, Barichello JM, Kikuchi H, Ishida T, Kiwada H.

Int J Pharm. 2007 Mar 21;333(1-2):62-9. Epub 2006 Oct 10.

PMID:
17097247
20.

Cellular delivery of siRNA mediated by fusion-active virosomes.

Huckriede A, De Jonge J, Holtrop M, Wilschut J.

J Liposome Res. 2007;17(1):39-47.

PMID:
17454402

Supplemental Content

Support Center